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Abstract
IMPORTANCE Although patients with chronic kidney disease (CKD) are routinely managed in
primary care settings, no nationally representative study has assessed the quality of care received by
these patients in Canada.
OBJECTIVE To evaluate the current state of CKDmanagement in Canadian primary care practices to
identify care gaps to guide development and implementation of national quality improvement
initiatives.
DESIGN, SETTING, ANDPARTICIPANTS This cross-sectional study leveraged Canadian Primary
Care Sentinel Surveillance Network data from January 1, 2010, to December 31, 2015, to develop a
cohort of 46 162 patients with CKDmanaged in primary care practices. Data analysis was performed
from August 8, 2018, to July 31, 2019.
MAINOUTCOMES ANDMEASURES The study examined the proportion of patients with CKDwho
met a set of 12 quality indicators in 6 domains: (1) detection and recognition of CKD, (2) testing and
monitoring of kidney function, (3) use of recommended medications, (4) monitoring after initiation
of angiotensin-converting enzyme inhibitors (ACEIs) or angiotensin II receptor blockers (ARBs), (5)
management of blood pressure, and (6) monitoring for glycemic control in those with diabetes and
CKD. The study also analyzed associations of divergence from these quality indicators.
RESULTS The cohort comprised 46 162 patients (mean [SD] age, 69.2 [14.0] years; 25 855 [56.0%]
female) with stage 3 to 5 CKD. Only 4 of 12 quality indicators weremet by 75% ormore of the study
cohort. These indicators were receipt of an outpatient serum creatinine test within 18 months after
confirmation of CKD, receipt of blood pressuremeasurement at any time during follow-up, achieving
a target blood pressure of 140/90mmHg or lower, and receiving a hemoglobin A1c test for
monitoring diabetes during follow-up. Indicators in the domains of detection and recognition of CKD,
testing andmonitoring of kidney function (specifically, urine albumin to creatinine ratio testing), use
of recommendedmedications, and appropriate monitoring after initiation of treatment with ACEIs or
ARBs were not met. Only 6529 patients (18.4%) with CKD received a urine albumin test within 6
months of CKD diagnosis, and 3954 (39.4%) had a secondmeasurement within 6months of an
abnormal baseline urine albumin level. Older age (85 years) and CKD stage 5 were significantly
associated with not satisfying the criteria for the quality indicators across all domains. Across age
categories, younger patients (aged 18-49 years) and older patients (75 years) were less likely to be
tested for albuminuria (314 of 1689 patients aged 18-49 years [18.5%], 1983 of 11 919 patients aged
75-84 years [61.6%], and 614 of 5237 patients aged85 years [11.7%] received the urine albumin to
creatinine ratio test within 6months of initial estimated glomerular filtration rate <60mL/min per
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Abstract (continued)
1.73 m2; P < .001). Patients aged 18 to 49 years were less commonly prescribed recommended
medications (222 of 2881 [7.7%]), whereas patients aged 75 to 84 years were prescribed ACEIs or
ARBsmost frequently (2328 of 5262 [44.2%]; P < .001).
CONCLUSIONS ANDRELEVANCE The findings suggest that management of CKD across primary
care practices in Canada varies according to quality indicator. This study revealed potential priority
areas for quality improvement initiatives in Canadian primary care practices.
JAMA Network Open. 2019;2(9):e1910704.
Corrected on September 13, 2019. doi:10.1001/jamanetworkopen.2019.10704
Introduction
Chronic kidney disease (CKD) is a frequently treated condition at health care systems, both globally
and within Canada, with a prevalence of approximately 10% in the general population.1-3 Most
patients with CKD are at low risk of progression to end-stage kidney disease (ESKD) and are ideally
managed in primary care settings.4 Organizations such as Kidney Disease: Improving Global
Outcomes, the UK National Institute for Health and Clinical Excellence,5 and the Canadian Society of
Nephrology6 provide recommendations regarding themanagement of patients with CKD to reduce
the risk of adverse consequences of ESKD and cardiovascular disease. Despite these guidelines,
variability in care continues.7-9
Regular quality audits at local, provincial or state, and national levels could identify variations in
care and inform resource allocation, primary care physician training, education, and other quality
improvement activities.10,11 Furthermore, assessment benchmarks for quality are the first step to
evaluating innovations aimed at creating high-functioning and sustainable health systems.12 A few
studies7,9,13 have examined quality of care for patients with CKD in primary care settings using
provincial (regional) data. To our knowledge, no studies have examined pan-Canadian performance
in meeting quality-of-care indicators for CKDmanagement in primary care, as has been done in other
settings.14-17
National chronic disease surveillance systems, such as the Canadian Primary Care Sentinel
Surveillance Network (CPCSSN), have been designed to facilitate national quality improvement
studies to improve chronic disease management.15-18 Understanding data from Canadian primary
care may indicate gaps in care processes and demonstrate a proof of concept for the use of CPCSSN
data to inform targeted priorities for improvement inmanagement of patients with chronic diseases.
The key objectives of this study were to define the current state of CKDmanagement in Canadian
primary care practices based on existing guidelines and to stratify key results by population
demographics.
Methods
Design and Participants
This cross-sectional study used a national database (CPCSSN data) to develop a cohort of patients
with CKDmanaged in primary care from January 1, 2010, to December 31, 2015 (Figure 1). Data
analysis was performed from August 8, 2018, to July 31, 2019. We examined prevalent CKD (defined
based on expert guideline criteria)19 during the study period and determined quality indicators for
CKD care in patients whomet the case criteria. Patients were identified as having CKD if they had at
least 2 estimated glomerular filtration rate (eGFR) measurements less than 60mL/min/1.73 m2 within
a period of at least 3 months but not more than 18months (Figure 2). Only those with moderate-to-
advanced CKD (stages 3-5) were eligible. Patients with ESKD undergoing dialysis or who had received
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a kidney transplant were excluded. We followed the Strengthening the Reporting of Observational
Studies in Epidemiology (STROBE) reporting guideline to outline the findings. This studywas approved
by the CPCSSN Surveillance and Research Standing Committee and the University of Alberta Health
Research Ethics Committee. The CPCSSN has received awaiver of the requirement to obtain individual
patient consent to include their deidentified data in its data set unless they have specifically opted out.
As data custodians, sentinels permit this use of the data on behalf of their patients.
Setting andData Sources
The CPCSSN is composed of 13 regional networks that form a national disease surveillance system
that collects primary care data from 9 of the 13 provinces and territories in Canada.20 Data in the
CPCSSN repository are derived from primary care electronicmedical records (EMRs) and are cleaned,
coded, deidentified, and made available to users for research, surveillance, evaluation, and quality
improvement purposes.21
Figure 1. Development of the Chronic Kidney Disease (CKD) Cohort
1 170 789 IndividuaIs in CPCSSN data base, 2010-2015 
1 037 987 Individuals with valid demographic information 
603 954 Individuals aged ≥18 y at the time of first recorded
eGFR test 
559 745 Individuals aged ≥18 y at the time of first recorded
eGFR test with ≥1 y of follow-up eGFR data 
46 162 Individuals with CKD, aged ≥18 y at time of first recorded
eGFR test, and with ≥1 y of follow-up eGFR data 
132 811 Excluded (individuals without valid age and sex information) 
44 209 Excluded (individuals without 1 y of follow-up eGFR data) 
513 583 Excluded (individuaIs without CKD)
434 024 Excluded
406 182 Individuals without an eGFR test, 2010-2015 
27 842 Individuals aged <18 y at the time of first
recorded eGFR test 
The steps of developing a cohort of patients with CKD
whoweremanaged in primary care between January
1, 2010, and December 31, 2015, from Canadian
Primary Care Sentinel Surveillance Network (CPCSSN)
data repository are shown. Chronic kidney diseasewas
defined as at least 2 estimated glomerular filtration
rate (eGFR) measurements less than 60mL/min per
1.73 m2 at least 90 days apart.
Figure 2. Decision Process for Identification of IndividualsWith Chronic Kidney Disease (CKD)
January
2010
January
2011
September 1, 2010
January
2012
January
2013
Blocked
phase
(90 days)
September
2010
-November
2010
 Qualifying phase
(3-18 mo)
December 2010
-December 2011
August 1, 2011
August 1, 2011-August 1, 2012
A sample timeline of the decision process followed to identify patients with CKD (defined
as having2 estimated glomerular filtration rate [eGFR] measurements <60mL/min
per 1.73 m2 within at least 3 months but not more than 18months) in the Canadian
Primary Care Sentinel Surveillance Network data repository. Qualifying eGFR indicates an
eGFR value less than 60mL/min per 1.73m2; blocked phase, period of 90 days after the
first qualifying eGFRmeasurement at which no second eGFRmeasurement was
considered confirmatory of CKD; qualifying phase, period of 3 to 18months after the first
qualifying eGFRmeasurement that a second eGFRmeasurement confirms CKD and
qualifies the patient to be included in the study; and follow-up period, 1 year after
confirmation of CKD to assess the use of appropriate medications.
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Definition andDerivation of Quality Indicators of CKDManagement
Quality indicators for CKD care in primary care practices were derived from the published expert
guideline and those developed by the Canadian experts. The Canadian Society of Nephrology
published a guideline for themanagement of CKD 2 years before the onset of this study in 2008.19
We examined and adapted 12 quality indicators based on previously published data and
guidelines.7,19 The indicators were categorized under the domains of detection and recognition of
CKD, testing andmonitoring of kidney function, use of recommendedmedications, monitoring after
initiation of treatment with angiotensin-converting enzyme inhibitors (ACEIs) and angiotensin II
receptor blockers (ARBs), management of blood pressure, andmonitoring for glycemic control
(Figure 3). The cutoff for being considered as having achieved each quality-of-care indicator was 75%
of patients who reached the target during the study period.
Covariates
To understand the variability in quality indicators, we divided the cohort of patients with CKD into 4
categories for subgroup analysis using validated CPCSSN case definitions: patients without
hypertension or diabetes, patients with hypertension only, patients with diabetes only, and patients
with hypertension and diabetes.22 For further analysis, we stratified quality indicator data by CKD
stage (stages 3-5), age category, and sex. All variables were extracted from patient EMRs available in
the CPCSSN data repository.
Statistical Analysis
Patient demographic and clinical characteristics were tabulated descriptively using proportions or
means as appropriate. The proportion of patients whomet the CKDmanagement criteria for the
quality indicators were calculated for the overall cohort and by comorbid subgroup, with χ2 tests of
the differences between subgroups indicating statistically significant differences in quality of care.
Figure 3. Overview of Quality of Care Indicators Studied
Detection and recognition of CKD
Testing and monitoring of kidney function
Patients receiving a UACR test within 6 mo of initial
eGFR <60 mL/min per 1. 73 m2
1
Patients receiving a UACR test within 6 mo of initial
positive UACR test result
2
Patients receiving an outpatient serum creatinine test
within 18 mo after confirmation of CKD 
3
Patients receiving a UACR test 
within 18 mo after confirmation of CKD
4
Use of recommended medications
Patients prescribed a statin at any time within 1 y
after confirmation of CKD
5
Patients prescribed ACEls or ARBs at any time within 1y
after confirmation of CKD 
6
Monitoring after initiation of ACEIs and ARBs 
Management of BP
Patients with confirmed CKD who receive an outpatient serum
creatinine test 7-30 d after initial ACEI or ARB prescription date
7
Patients receiving BP measurement at any time8
Patients receiving BP measurement
within 6 mo of initial eGFR <60 mL/min per 1.73 m2
9
Monitoring for glycemic control 
Patients with an eGFR <60 mL/min per 1.73 m2 and diabetes
receiving an HbA1c test within the first and second years 
12
Patients with an eGFR <60 mL/min per 1.73 m2
who achieved a target BP of ≤140/90 mm Hg
10
Patients with an eGFR <60 mL/min per 1.73 m2
who also had evidence of albuminuria and/or diabetes and
achieved a target BP of ≤130/80 mm Hg
11
The 12 quality indicators for patients with chronic kidney disease (CKD) in primary care
used in the study are shown. The 12 indicators were categories under the domains of
detection and recognition of CKD, testing andmonitoring of kidney function, use of
recommended medications, monitoring after initiation of treatment with angiotensin-
converting enzyme inhibitors (ACEIs) and angiotensin II receptor blockers (ARBs),
management of blood pressure, andmonitoring for glycemic control. BP indicates blood
pressure; eGFR, estimated glomerular filtration rate; HbA1c, glycated hemoglobin; and
UACR, urine albumin to creatinine ratio.
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We used binomial regressionmodels to identify key demographic characteristics associated with not
receiving specified care. We reported the estimated risk ratio (RR) and corresponding 95% CI for
each association for the variables assessed and presented these graphically using forest plots.
Missing data were handled by listwise deletion because themissingness was assumed to be random.
All analyseswere performed using Stata, version 14.2 (StataCorp).23 A 1-sided P < .05was considered
to be statistically significant.
Results
Baseline Demographics
The baseline cohort was composed of 46 162 patients (mean [SD] age, 69.2 [14.0] years; 25 855
[56.0%] female) from primary care practices in Canada identified with stages 3 to 5 CKD during the
study period. A total of 24 368 patients (68.6%) had stage 3A CKD, with a mean eGFR value of 47.7
mL/min per 1.73 m2. A total of 38 545 patients (83.5%) had at least 1 comorbid condition. A total of
7603 patients (16.5%) had neither diabetes nor hypertension, 6770 (14.7%) had diabetes without
hypertension, 16 930 (36.7%) had hypertension only, and 14 859 (32.2%) had both diabetes and
hypertension (Table 1).
Overview of Quality of CKDManagement
Only 4 quality indicators were successfully met in 75% ormore of the cohort (Table 2 and eFigure 1
in the Supplement). These indicators were receipt of an outpatient serum creatinine test within 18
months after confirmation of CKD, receipt of blood pressure measurement at any time during
follow-up, achieving a target blood pressure of 140/90mmHg or lower, and receiving a hemoglobin
A1c test for monitoring diabetes during follow-up. These indicators were in the domains of testing
andmonitoring of kidney function (eGFR), management of blood pressure, and glycemic control.
Criteria for the remaining indicators (in the domains of detection and recognition of CKD [monitoring
Table 1. Cohort Characteristics Overall and by Comorbid Statusa
Characteristic
Overall
(N = 46 162)
Patients With CKD
P Value
Without Diabetes or
Hypertension
(n = 7603 [16.5%])
With Diabetes
(n = 6770 [14.7%])
With Hypertension
(n = 16 930 [36.7%])
With Diabetes and
Hypertension
(n = 14 859 [32.2%])
Age group, y
18-49 4535 (9.8) 1017 (13.4) 1471 (21.7) 763 (4.5) 1284 (8.6)
<.001
50-64 11 137 (24.1) 1718 (22.6) 2172 (32.1) 2836 (16.8) 4411 (29.7)
65-74 12 286 (26.6) 1785 (23.5) 1546 (22.8) 4501 (26.6) 4454 (30.0)
75-84 12 840 (27.8) 1971 (25.9) 1220 (18.0) 5990 (35.4) 3659 (24.6)
≥85 5364 (11.6) 1112 (14.6) 361 (5.3) 2840 (16.8) 1051 (7.1)
Age, mean (SD), y 69.2 (14.0) 68.6 (16.1) 62.2 (15.5) 73.5 (12.1) 67.8 (12.4)
Female sex 25 855 (56.0) 4659 (61.3) 3071 (45.4) 10 700 (63.2) 7425 (49.9) <.001
CKD stage at first
qualifying eGFR
measurementb
3A 24 368/35 517 (68.6) 5270/6951 (75.8) 2300/3484 (66.0) 10 749/15 666 (68.6) 6049/9416 (64.2)
<.001
3B 845/35 5177 (23.8) 1296/6951 (18.6) 841/3484 (24.1) 3846/15 666 (24.6) 2474/9416 (26.3)
4 2290/35 517 (6.5) 304/6951 (4.4) 266/3484 (7.6) 942/15 666 (6.0) 778/9416 (8.3)
5 402/35 517 (1.1) 81/6951 (1.2) 77/3484 (2.2) 129/15 666 (0.8) 115/9416 (1.2)
eGFR, mean (SD),
mL/min per 1.73 m2
47.7 (10.5) 49.4 (10.0) 46.8/3484 (11.4) 47.8 (10.1) 46.6 (10.9) NA
Abbreviations: CKD, chronic kidney disease; eGFR, estimated glomerular filtration rate;
NA, not applicable.
a Data are presented as number or number/total number (percentage) of patients unless
otherwise indicated.
b First qualifying eGFRmeasurement is the first measurement of 60mL/min per 1.73 m2
or less.
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of albuminuria], use of recommendedmedications, and appropriate monitoring after initiation of
treatment with ACEIs or ARBs) were not met in at least 75% of the cohort.
Detection and Recognition of CKD andMonitoring of Kidney Function
Overall, 6529 patients with CKD (18.4%) received follow-up urine albumin to creatinine ratio (UACR)
testing within 6months of CKD diagnosis. In subgroup analysis, detection was significantly less
common among patients without diabetes or hypertension (472 [6.8%]) andmost common among
patients with diabetes and hypertension (3321 [35.3%]) (P < .001) (Table 2). A total of 3954 patients
(39.4%) had UACR confirmatory testing within 6 months after a positive albuminuria test result. A
Table 2. Quality-of-Care Indicators for CKD, Blood Pressure, and Glycemic Control Overall and by Comorbid Status
Domain and Quality Indicator
No. (%) of Patients
P ValueOverall
CKD
Without Diabetes or
Hypertension With Diabetes With Hypertension
With Diabetes and
Hypertension
Detection and recognition of CKD
Patients receiving UACR test within
6 mo of initial eGFR <60 mL/min
per 1.73 m2
6529 (18.4) 472 (6.8) 1129 (32.4) 1607 (10.3) 3321 (35.3) <.001
Patients receiving UACR test
within 6 mo of initial positive UACR
test result
3954 (39.4) 254 (43.9) 1130 (38.4) 413 (35.5) 2157 (40.4) .001
Testing and monitoring of kidney
function
Patients with an outpatient SCr test
in the 18 mo after the confirmation
of CKD
27 221 (85.5) 4552 (77.3) 2913 (89.2) 11 668 (84.5) 8088 (91.2) <.001
Patients with a UACR test in the
18 mo following the confirmation
of CKD
8599 (27.0) 581 (9.9) 1485 (45.5) 2219 (16.1) 4314 (48.7) <.001
Use of recommended medications
Patients prescribed a statin any
time in the 1 y after the
confirmation
of CKD
11 672 (36.7) 1198 (20.3) 1399 (42.9) 4613 (33.4) 4462 (50.3) <.001
Patients prescribed an ACEI or ARB
any time in the 1 y after the
confirmation of CKD who have
evidence of proteinuria and/or
diabetes
6964 (30.5) 57 (27.3) 1278 (18.9) 551 (54.9) 5078 (30.5) <.001
Monitoring after initiation of treatment
with ACEIs or ARBs
Patients with confirmed CKD who
receive an outpatient SCr test 7-30 d
after initial ACEI or ARB prescription
date
659 (26.7) 69 (26.3) 73 (27.8) 334 (28.5) 183 (23.8) .14
Management of BP
Patients receiving BP measurement
at any time
34 941 (75.7) 4998 (65.7) 5120 (75.6) 13 064 (77.2) 11 759 (79.1) <.001
Patients receiving BP measurement
within 6 mo of initial eGFR
<60 mL/min per 1.73 m2
13 914 (30.1) 1904 (25.0) 1263 (18.7) 6332 (37.4) 4415 (29.7) <.001
Patients with eGFR <60 mL/min per
1.73 m2 achieving a target BP of
≤140/90 mm Hg
15 467 (81.4) 2574 (89.2) 1730 (86.8) 6582 (78.9) 4581 (79.3) <.001
Patients with eGFR <60 mL/min per
1.73 m2 achieving a target BP of
≤130/80 mm Hg, who have evidence
of proteinuria and/or diabetes
4689 (59.6) 81 (71.1) 1249 (67.8) 339 (53.2) 3020 (57.3) <.001
Monitoring for glycemic control,
patients with eGFR <60 mL/min per
1.73 m2 and diabetes who have HbA1c
tested within the first and second years
0-1 y 11 073 (85.9) NA 3018 (85.7) NA 8055 (86.0) .66
1-2 y 8626 (66.9) NA 2266 (64.4) NA 6360 (67.9) <.001
Abbreviations: ACEI, angiotensin-converting enzyme inhibitor; ARB, angiotensin II
receptor blocker; BP, blood pressure; CKD, chronic kidney disease; eGFR, estimated
glomerular filtration rate; HbA1c, glycated hemoglobin; NA, not applicable; SCr, serum
creatinine; UACR, urine albumin to creatinine ratio.
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total of 27 221 patients (85.5%) received a follow-up serum creatinine and eGFR test in the 18months
after the confirmation of CKD. In subgroup analysis, there was a statistically significant difference in
the number of patients receiving an outpatient serum creatinine test: 8088 patients (91.2%) with
comorbid hypertension and diabetes vs 4552 patients (77.3%) without comorbid diabetes or
hypertension (P < .001). Overall, 8599 patients (27.0%) received a follow-up UACR test in the 18
months after the confirmation of CKD. In subgroup analysis, there was a statistically significant
difference in the number of patients receiving a follow-up UACR: 4314 patients (48.7%) with
comorbid hypertension and diabetes vs 581 patients (9.9%) without comorbid diabetes or
hypertension (P < .001) (Table 2).
Use of RecommendedMedications andAppropriateMonitoring After Initiation
of TreatmentWith ACEIs or ARBs
A total of 11 672 patients (36.7%) were prescribed statins, and 6964 (30.5%) were prescribed ACEIs
or ARBs within 1 year of confirmation of CKD. Overall, 5078 patients (30.5%) with evidence of
albuminuria and/or diabetes were prescribed ACEIs or ARBs within 1 year of CKD diagnosis. Both
ACEIs and ARBs weremost commonly prescribed for patients with comorbid hypertension (551
[54.9%]) and least commonly prescribed for those with comorbid diabetes (1278 [18.9%]) (Table 2).
Only 659 patients (26.7%)with confirmed CKD received an outpatient serum creatinine test 7 to 30
days after the initial ACEI or ARB prescription date (Table 2). Patients with comorbid diabetes and
hypertension (183 [23.8%]) were tested least frequently, whereas those with hypertension only (334
[28.5%]) were testedmost frequently.
Management of Blood Pressure andMonitoring for Glycemic Control
A total of 34 941 patients (75.7%) had at least 1 blood pressuremeasurement during the study period.
Subgroup analysis revealed that blood pressure had beenmeasured for 4998 (65.7%) of those with
CKD but without diabetes or hypertension and for 11 759 (79.1%) of those with diabetes and
hypertension (Table 2). Only 13914 patients (30.1%) had their blood pressure measured within 6
months of a qualifying eGFRmeasurement. Variations among comorbid groups revealed that blood
pressure was more commonly measured among those with hypertension (6332 [37.4%]) (Table 2).
Overall, 15 467 patients (81.4%) met the guideline-concordant blood pressure target of 140/90 mm
Hg or less (Table 2). A total of 4689 patients (59.6%) with albuminuria and/or diabetes met the
guideline-concordant target blood pressure measure of 130/80mmHg or less (Table 2). Most
patients with CKD and diabetes had a glycated hemoglobin test within the first (11 073 [85.9%]) and
second (8626 [66.9%]) years of the study (Table 2).
Variations Across Disease Stage, Comorbid Status, Age, and Sex
Across CKD stages, delivery of guideline-concordant care was more commonwith each progressive
stage with the exception of stage 5 (eTable 1 in the Supplement). Older age (85 years) and CKD
stage 5 were significantly associated with not satisfying the criteria for the quality indicators across
all domains (eTable 1 and eTable 2 in the Supplement). Across age categories, younger patients (aged
18-49 years) and older patients (75 years) were less likely to be tested for albuminuria (314 of 1689
patients aged 18-49 years [18.5%], 1983 of 11 919 patients aged 75-84 years [61.6%], and 614 of 5237
patients aged85 years [11.7%] received the UACR test within 6months of initial eGFR <60mL/min
per 1.73m2; P < .001) (eTable 2 in the Supplement). Patients aged 18 to 49 years were less commonly
prescribed recommendedmedications (222 of 2881 [7.7%]), whereas patients aged 75 to 84 years
were prescribed ACEIs or ARBs most frequently (2328 of 5262 [44.2%]) (P < .001) (eTable 2 in the
Supplement). Stratification by sex revealed that for 5 of 7 indicators (detection and recognition of
CKD [2 indicators], testing and monitoring of kidney function [2 indicators], and use of
recommendedmedications [1 indicator]), care was more likely to conform to recommendations for
men than for women (eTable 3 in the Supplement).
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Factors AssociatedWith Lower Achievement of Quality Indicators
The factors associated with not receiving a UACR test within 6months and 18months of a qualifying
eGFR are shown in eFigure 2 and eFigure 3 in the Supplement. Factors associated with not being
prescribed a statin are given in eFigure 4 in the Supplement, for not being prescribed ACEIs or ARBs
for patients who had evidence of proteinuria and/or diabetes in eFigure 5 in the Supplement, and for
not receiving a blood pressure measurement and achieving targets in eFigures 6-9 in the
Supplement.
Variations Across Physician Characteristics
Overall, no association between age or sex (or a combination) of physician and adherence to
guidelines was found (eTable 4 in the Supplement).
Discussion
In this national study of more than 46000 Canadian individuals with stage 3 to 5 CKDmanaged in
primary care, we identified gaps in the quality of CKD care related to monitoring and testing for
albuminuria as well as use of recommendedmedications to reduce risk of progression to ESRD and
prevent cardiovascular events. To our knowledge, this is the first study to examine quality indicators
for CKDmanagement in Canadian primary care at a national level and to study associations of
variance.
Overall, results of this study suggest a need to understand underlying reasons for and
appropriateness of variance in particular quality indicators. Among the 12 indicators examined, only
4 revealed satisfactory performance, thus providing important opportunities to improve CKD
management. The 4 quality indicators that revealed satisfactory performance were in the domains
of testing and monitoring of kidney function (ie, eGFR measurements after confirmation of CKD),
management of blood pressure, andmonitoring for glycemic control. The domains for improvement
in the quality of carewere concernedwith the detection and recognition of CKD risk associatedwith
cardiovascular disease (ie, albuminuria measurements), use of recommended medications, and
monitoring of kidney function after prescription of ACEIs and ARBs.
We found that the presence of stage 5 CKD and older ages were associated with a lower
likelihood of meeting the quality indicators. There are several possible reasons why these gaps may
exist. First, these findings may relate to clinical decisions that reflect increased patient complexity or
a more supportive approach to care. Multimorbidity is common in older adults,24 meaning that
single-disease approaches to guiding treatment may be inappropriate and potentially harmful if
treatment targets are applied indiscriminately while ignoringmedical complexity. For example, it may
be appropriate to not prescribemedications for a specific individual given their multimorbidity even
though it may seem appropriate based on guidelines.25,26 The reasons are complex and include drug-
drug and drug-disease interactions, a patient’s treatment priorities, the overall burden of medical
care, and limited lifespan benefit. Understanding the difference between appropriate variance and
inappropriate (low-quality) care can inform future quality improvement initiatives. Evidence-based
medicine is predicated on patient-centered decision-making, which is one of the coremechanisms by
which primary care achieves better population outcomes. In this model, individuals are free to
choose not to engage with recommended care, and it is valid for a patient to make a choice that is
consistent with their values despite incongruence with guideline recommendations.
After stratification by stage of CKD and sex, with the general exception of stage 5, each
progressive stage of CKDwas associated with increased conformity to guideline-recommended care
for 5 of 7 quality indicators in the domains of detection and recognition of CKD, testing and
monitoring of kidney function, use of recommendedmedications, andmonitoring of kidney function
after an ACEI or ARBwas prescribed. This findingmight be related to early stages of CKD often
remaining undiagnosed; more advanced stages of CKD are more readily identified and therefore
better managed. Findings that reveal sex differences in disease management have been reported in
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different disciplines (eg, women receive less guideline-concordant care for myocardial infarction27
and heart failure28). Specific to CKD, the sex differences associatedwith heart failure described in the
literature relate to disease epidemiology, prognosis, and progression.29,30 The novel finding of sex
differences in quality of care for CKD is an area for future study. Possible implications for sex
differences in disease management could include the development of new approaches to disease
identification andmodified training materials for medical practitioners.11,30
Amajor implication to practice and quality improvement initiatives is that themanagement of
CKD varied across indicators. Theworst-performing indicator and a finding of significant concern was
that only 18.4% of patients received a follow-up UACR test within 6 months of CKD diagnosis. The
association of older age with assessed variables provides direction for the development of quality
improvement interventions. One possible explanation is that some health care professionals may not
consider an eGFRmeasurement within the range of stage 3A CKD to indicate a risk of disease
progression to ESKD in older people. Theymight consider such ameasurement as reflecting the
physiologic changes associated with aging because CKD seldom progresses in the absence of
albuminuria. Thus, some experts have asked for an age-calibrated classification for CKD.31 The other
quality indicator at variance with guideline concordance was follow-up albuminuria tests when
indicated, whichwas notwell met. Associations for not receiving this test included older age and rural
residency, the latter reflecting previous findings that patients with CKD living in rural settings may
receive lower quality of care than patients living in urban settings.32 The rural-urban health disparity
has been the subject of many reports33,34 and initiatives in Canada, but work still needs to be done
to address this issue. These findings may facilitate further research and investment into alternative
modes of health care delivery to patients in rural communities, such as telemedicine and electronic
consultation. However, the increased likelihood of detection in the subgroup with diabetes and
hypertension suggests an increased understanding of risk factors for albuminuria in CKD.
Furthermore, the indicator for the domain of monitoring ACEI and ARB use (ie, outpatient
serum creatinine testing 7-30 days after the initial prescription date) was not met and is an area for
further work with the aim of understanding variation and appropriateness as a basis for quality
improvement. Performance associatedwith this quality indicator improved as CKD stage progressed,
which suggests greater awareness of the importance ofmonitoringmedication use during advanced
stages of the disease.
Results related to blood pressure quality indicators were mixed. Most patients had their blood
pressure measured at least once during the study, whereas only a few patients had it measured
within 6 months of CKD diagnosis. The quality indicator of patients who met the guideline-
concordant blood pressure target of 140/90mmHg or less was met; however, there was room for
improvement in the quality indicator of patients with proteinuria or diabetes meeting the guideline-
concordant blood pressure target of 130/80 mmHg or less. The variables significantly associated
with not achieving a target blood pressure were older age, stage 3A CKD, and living in rural areas.
Older age is associated with increased risk of comorbidities; therefore, elevated blood pressure is
common. Treatment of hypertension with pharmacotherapy in older age is also associated with an
increased risk of falls and serious injury, and treatment thresholds are therefore a balance of risks and
benefits requiring amore individualized approach to care.35 The finding that thosewith stage 3A CKD
were unlikely to achieve a target blood pressure remains unexplained. Our finding that living in rural
areas was associated with nonconformance with target blood pressure levels is supported by results
from a population-based study9 that found that patients with diabetes and CKD living in rural or
remote parts of Alberta, Canada, were less likely to meet process-based outcomes (eg, glycated
hemoglobin and albuminuria measurements, use of recommendedmedications) than were their
urban counterparts. These findings underscore the importance of targeted intervention to address
geographic disparities in CKD care. For instance, the use of electronic consultations (asynchronous
electronic communication between physicians) was found to improve access to specialist advice in
remote communities in Canada.36
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In addition to the patient-related factors (demographic, clinical, and laboratory) outlined in our
results, we specifically examined physician factors and found no association between age or sex (or
a combination) of physician and adherence to guidelines. It is important to recognize the wider
context of physician factors in implementation of guideline recommendations, which has
implications in understanding concordance and variation.37 For example, the volume of guideline
recommendations for primary care is increasing at a rate that is not sustainable for implementation.
For a primary care physician, it would take 7 hours a day to follow all preventive recommendations
and 10 hours a day to follow recommendations for 10 chronic diseases. These data are based on an
assessment in the mid-2000s, and guideline proliferation continues.37,38 How should a primary care
physician prioritize smoking cessation vs urine protein analysis? Primary care physicians may
prioritize patients according to which factor seems likely to bemost associated with patients’
outcomes and focus on quality improvement initiatives that aremost important for population health
improvement. This approachmay improve implementation and adoption of guidelines in general.
This study builds on a previous study39 that used data from CPCSSN to estimate the prevalence
of CKD beingmanaged in primary care practices across Canada. This current work provides an
in-depth assessment of the current practice pattern and variations in care for CKD to understand
areas of appropriate and inappropriate variation within the context of multimorbidity, patient-
centered care, and primary care service delivery to support quality improvement that is most
meaningful for patients.
Limitations
This study had several limitations. We limited our analysis to data from patients with moderate to
advanced stages of CKD (stages 3-5) because patients with early stages of CKD cannot be readily
identified based on eGFRmeasurements alone. As a result, we were not able to capture the quality
of care received by patients with early-stage CKD, which is often asymptomatic. Another limitation of
the study relates to the representativeness of the cohort to the general Canadian population. Our
cohort tended to be older than the general Canadian population and included slightly more women
than men than in the general population. Moreover, data in the CPCSSN repository are based on
information available from the source EMRs; gaps in data quality (particularly related to
completeness and capture) may have underestimated actual clinical performance associated with
the indicators considered in this study, which has limited our ability to use other CKDmarkers, such
as dipstick proteinuria. Furthermore, the nature of the data made it difficult to establish temporality
with clinical situations that could limit the application of some of the quality indicators in practice,
for example, the use of ACEIs or ARBs in the context of hyperkalemia and/or hypotension.
In addition, even though the Canadian Society of Nephrology guideline for themanagement of
CKDwas published 2 years before the onset of this study, differential uptake of its recommendations
among primary care physicians could be fraught with inherent complexities. Physician-related
factors (eg, age, sex, years in practice, time, and resources), patient factors, and practice
environment contextual factors (academic vs community based, rural vs urban, and regulation)
inform adoption of guidelines into practice.40 Moreover, it is also widely recognized that lack of
awareness of the availability of the guideline and familiarity with its details were common barriers to
implementation in patient care.41 These issues are relevant to the interpretation of our findings.
Some primary care physicians in Canadamight not have been aware of the existence of the CKD
management guideline, and this awareness might have come to them over time in their practice
outside the scope of the study. Clinical practice guidelines are often produced by specialty societies,
as was the CKDmanagement guideline, and it would be challenging for primary care physicians to
keep up to date and adopt all of the guidelines into practice. These data may provide an opportunity
to engage with relevant primary care organizations in Canada, such as the College of Family
Physicians of Canada and other primary care professional societies, to close the identified gaps and
facilitate uptake of the guideline for optimal kidney care.
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Conclusions
The findings suggest that management of CKD across primary care practices in Canada varies
according to quality indicator. This study revealed potential priority areas for quality improvement
initiatives in Canadian primary care practices.
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SUPPLEMENT.
eFigure 1. Performance related to quality indicators
eFigure 2. Associations for not receiving a UACR test within 6months following the confirmation of CKD
eFigure 3. Associations for not receiving a UACR test within 18months following the confirmation of CKD
eFigure 4.Associations for not being prescribed a statin at any time in the 1 year following the confirmation of CKD
eFigure 5. Associations for not being prescribed an ACE inhibitor or ARB at any time in the 1 year following the
confirmation of CKD
eFigure 6. Associations for not receiving a blood pressure measurement at any time
eFigure 7. Associations for not receiving a blood pressure measurement within six months of initial eGFR
measurement
eFigure 8. Associations for not achieving a target BP of140/90mmHg, among those with blood pressure
measure after CKD diagnosis
eFigure 9. Associations for not achieving a target BP of130/80mmHg, among those with confirmed CKD and
evidence of albuminuria and/or diabetes
eTable 1.Quality of care indicators for CKD, overall and by comorbid status, and disease stage
eTable 2.Quality of care indicators for CKD, overall and by comorbid status and age categories
eTable 3.Quality of care indicators for CKD, overall and by comorbid status, and sex
eTable 4. Variations of quality of care indicators for CKD, across physician characteristics (age and gender)
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